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Pharmacogenomics (PGx) relates to the study of genetic factors determining variability in drug response. Implementing PGx testing in paediatric patients can enhance
drug safety, helping to improve drug efficacy or reduce the risk of toxicity. Despite
its clinical relevance, the implementation of PGx testing in paediatric practice to date
has been variable and limited.
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As with most paediatric pharmacological studies, there are well-recognised barriers
to obtaining high-quality PGx evidence, particularly when patient numbers may be
small, and off-label or unlicensed prescribing remains widespread. Furthermore, trials
enrolling small numbers of children can rarely, in isolation, provide sufficient PGx evidence to change clinical practice, so extrapolation from larger PGx studies in adult
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patients, where scientifically sound, is essential.
This review paper discusses the relevance of PGx to paediatrics and considers implementation strategies from a child health perspective. Examples are provided from
Canada, the Netherlands and the UK, with consideration of the different healthcare
systems and their distinct approaches to implementation, followed by future recommendations based on these cumulative experiences.
Improving the evidence base demonstrating the clinical utility and cost-effectiveness
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of paediatric PGx testing will be critical to drive implementation forwards. International, interdisciplinary collaborations will enhance paediatric data collation, interpretation and evidence curation, while also supporting dedicated paediatric PGx
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educational initiatives. PGx consortia and paediatric clinical research networks will
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continue to play a central role in the streamlined development of effective PGx
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implementation strategies to help optimise paediatric pharmacotherapy.
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1 | PHARMACOGENOMICS: AN
I N T R O D U CT I O N

T A B L E 1 Examples of PGx stratification of patient groups that are
clinically relevant to paediatrics18

Pharmacogenomics (PGx) relates to the study of genetic factors deter-

PGx patient
group

mining variability in drug response, in terms of both efficacy and toxic-

Responders

Ivacaftor therapy for cystic fibrosis patients with
specified CFTR mutations: G551D, G1244E,
G1349D, G178R, G551S, S1251N, S1255P,
S549N or S549R

Nonresponders

CYP2D6 poor metabolisers: Limited conversion of
codeine to morphine: Recommend prescription
of alternative analgesic instead

Differential
responders

CYP2C19 polymorphisms affect voriconazole
pharmacokinetics: Genotype-guided dosing can
help to optimise paediatric voriconazole
therapy19

ity.1 It has long been known that individuals respond differently to
medicines and, over the last two decades, numerous peer-reviewed
publications have promised imminent benefits of precision medicine,
with many highlighting pharmacogenomic strategies as a core component of this long awaited revolution in healthcare.2 There is extensive
literature dedicated to the clinical utility of PGx, which is largely
focused on adult patients,3–5 on whom the majority of PGx research
is based. The challenges to implementation of pharmacogenomic testing within routine healthcare are well described.6–9 The importance of

CYP2D6 ultra-rapid metabolisers have increased
conversion of codeine to morphine, and this PGx
variability is an important factor contributing to
the EMA decision to make codeine use
contraindicated in children under 12 years old20

PGx has been recognised by the drug regulatory agencies, with the
European Medicines Agency (EMA) describing PGx as an “integral part
of the development and post-authorization (marketing) phase for a
number of medicines, with significant impact on the management of
their benefits and risks in clinical use”.10–12 However, the perceived
relevance and familiarity of PGx to healthcare professionals working

At risk of
severe ADR

in paediatrics remain limited in most settings,13 and the implementation of pharmacogenomic testing in paediatrics is also limited.14
and considers the pros and cons of different implementation strategies from a child health perspective. Examples are provided from

HLA-B*15:02 allele predisposes to carbamazepine
induced Stevens–Johnson syndrome (SJS) and toxic
epidermal necrolysis (TEN), in patients from
Southeast Asian countries21

Canada, the Netherlands, and the UK, with consideration of the distinct healthcare systems, different approaches to implementation and
its coordination at a national level, followed by future recommenda-

1.1
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TPMT genetic polymorphisms resulting in TPMT
deficiency can predispose to potentially fatal
myelotoxicity with thiopurine therapy (e.g.,
6-MP; discussed further in text below)
HLA-B*5701 allele predisposes to abacavir
hypersensitivity: As the reaction is severe, the
drug is contraindicated.

This review paper discusses the relevance of PGx to paediatrics

tions based on these experiences to date.

Clinically relevant examples

Abbreviations: CFTR, cystic fibrosis transmembrane conductance
regulator; EMA, European Medicines Agency; TPMT, thiopurine
S-methyltransferase; 6-MP, 6-mercaptopurine.

Pharmacogenomic testing: An overview

The aim of a pharmacogenomic test is to improve either the safety or

that would alter the choices made by the prescriber, and that would

effectiveness of a pharmacological therapy, or both. This is achieved

significantly alter the balance of benefit to harm for the individual

by using a patient's pharmacogenetic data (i.e., the elements of their

patient.22 In many adult PGx panel-based studies, actionable PGx vari-

genetic information that are of relevance to drug therapy) to inform

ants have been identified in more than 90% of patients.23,24

prescription decision making.15 To be deemed relevant to clinical

Evidence-based classifications of actionability of drug/gene pairs are

practice, the genetic information obtained from a PGx test must be a

available from PGx practice guidelines consortia, which are discussed

robust predictor of drug response;1 however, the degree of the genet-

further below.

ically determined variability in drug response can vary considerably

PGx testing can be either reactive or pre-emptive. Reactive test-

(ranging from 20–95% depending on the drug concerned16). In com-

ing occurs at (or close to) the point of prescription of a drug paired

plex disease genetics (e.g., hypertension, type 2 diabetes, schizophre-

with a known pharmacogene (i.e., the gene of relevance to the clini-

nia), there are multiple genes of interest, each producing small

cal pharmacology of that particular compound). This process requires

individual effects. However, exposure of the body to medication is a

a prompt turnaround time to ensure the result is available in time to

new event, in evolutionary terms, and there is evidence that genetic

inform the relevant prescription.19 In contrast, pre-emptive testing

variants affecting medicines have, overall, larger effect sizes aiding

involves prospective PGx testing, before prescription of the relevant

their potential clinical utility.17

drug(s) is required. Here, results must be accessible within the elec-

A PGx test result may detect a genetic predisposition to an

tronic health record (EHR), and future prescribers need to be aware

adverse drug reaction (ADR), or differentiate between drug

of the existence of actionable PGx results, and know what action to

responders and drug non-responders, or it may indicate that a differ-

take.19 In addition, when utilising an EHR, clinical decision support

ent dose of the drug—or in some cases a different class of drug

(CDS) systems are often also used. At least 20 different

altogether—is required (Table 1).1 Actionable PGx results are those

pharmacogenomic CDS systems have been, or are being, developed,

3

BARKER ET AL.

with the majority embedded within EHR systems.20 An ideal CDS

child should change the choices made by a paediatrician (or a physi-

will inform the clinician of the clinically relevant PGx finding before

cian looking after the same patient in future during adulthood) if pre-

they prescribe, including drug–drug interactions, while at the same

scribing the relevant drug(s). Therefore, PGx information needs to be

time being sophisticated enough to work with dose range checking

available and interpretable according to updated evidence-based pae-

processes (as PG may require dose alteration to achieve clinical effi-

diatric PGx recommendations. While it is true that PGx will not be

cacy, while avoiding alert fatigue in the users). Some evaluation of

directly relevant for every child, nor will it be relevant for every pre-

CDS for pharmacogenomics has been presented, but more will be

scription. This does not mean, however, that appropriate PGx testing

required.20

should not be available as part of routine care for those children for

The approaches for PGx testing can include targeted genotyping

whom it is relevant. It also should not matter if the prescribing clini-

technologies, which may focus on a single pharmacogene (if reactive

cian is the one who ordered the test, or is even located in the same

testing is chosen) or a number of pharmacogenes within a PGx

institution, as these data should be shared to all prescribers to avoid

panel,21 or may employ next generation sequencing techniques

unnecessary repetition of tests (which entails potential harms for the

(e.g., whole exome or whole genome sequencing), which can be used

child and additional financial costs). Currently, the limited availability

with virtual (bioinformatics-based) PGx panels,18,25–29 although the

of PGx testing and clear paediatric PGx guidelines presents a major

latter is largely restricted to research contexts at present.

obstacle, in addition to the need for enhanced PGx evidence in
children.
To overcome this, scaling up of new, validated testing strategies

1.2
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PGx practice guidelines consortia

for routine implementation within healthcare systems is required, but
can present numerous challenges. Traditionally, paediatric pharmacol-

The gap in the use of research discoveries to guide clinical practice—

ogy research studies and implementation strategies to update drug

the so-called “Valley of Death”—is well known. To address this, and

labelling and evidence-based guidelines have often faced long delays

aid the dissemination of PGx data and implementation into clinical

in comparison to the equivalent timelines in adult medicine.35 Typi-

practice, a number of PGx consortia have evolved. These include

cally, this delay arises due to various factors, including practical, ethi-

CPIC, The Pharmacogenomics Knowledge Base (PharmGKB), the

cal and financial barriers to research in children, many of which are

Canadian Pharmacogenomics Network for Drug Safety (CPNDS) and

now largely historical, thanks to coordinated global efforts to improve

the Dutch Pharmacogenetics Working Group.30–33 Consortia mem-

the pace of paediatric medicines research.36

bers include representatives from many different disciplines, including

The majority of prescriptions for children are prescribed in the

physicians, pharmacists and clinical scientists, with relevant expertise

community,37 with medicines most commonly prescribed by a GP or

in clinical pharmacology and therapeutics (CPT), genetics and numer-

Community Paediatrician. In contrast, the focus of interest for PGx, at

ous relevant subspecialty areas. These consortia disseminate

least at first, is likely to be in prescriptions issued for medicines with

evidence-based, peer-reviewed, updated and curated PGx practice

narrow therapeutic ranges, variable efficacy, dose limiting toxicity,

guidelines, which consider all aspects of PGx including variation in risk

relatively frequent PGx-related ADRs, or intensive monitoring require-

according to ethnicity. Clear, well-referenced knowledge summaries

ments. Therefore, the majority of paediatric prescriptions for which

are also published, for example those dedicated to so-called Very

PGx is relevant will, at least initially, be in hospitals. In keeping

Important Pharmacogenes (VIPgenes: defined as genes with well-

with this, selected PGx testing is already routinely available in

documented information regarding the relationship with a drug's phar-

certain specialist settings, such as in paediatric haemato-oncology

macokinetics/pharmacodynamics [PKPD]).33 Notably, these consortia

where thiopurine S-methyltransferase (TPMT) testing is routine

also provide information about when a PGx test should not be used to

(or mandatory) for patients due to receive 6-mercaptopurine ther-

guide prescribing (denoted, for example, by CPIC assigning act-

apy.38 Relevant stakeholders from both primary and secondary care

ionability levels C and D, which signifies that a specified gene/drug

settings need to be prospectively involved in implementation plan-

pair is not actionable).31 There are methodological differences in the

ning, as discussed further below.

evidence appraisal approaches used by different consortia, which war-

With the mainstreaming of genomic medicine rapidly changing

rant more detailed consideration when they lead to differing recom-

the healthcare landscape,39 increasing numbers of children and new-

mendations regarding the actionability of PGx variants encountered in

borns are undergoing whole genome sequencing (WGS).40 In particu-

clinical practice.

34

lar, the role of diagnostic WGS (or WES [whole exome sequencing])
in paediatric and neonatal intensive care settings is growing,41,42 and
in addition, pre-existing WES/WGS data can be re-analysed to inves-

2 | THE RATIONALE FOR IMPLEMENTING
P G X TE S T I N G I N C H I L D R E N

tigate PGx variants.43 There have also been recent discussions about
whether WGS may be introduced as part of routine newborn screening.44,45 Since PGx testing can either be pre-emptively integrated into

While the rationale underlying PGx testing is largely equivalent for

WGS for diagnostic reasons—or introduced as a separate “routine”

adults and children, the relevant principles are summarised here from

(or reactive) test in its own right (e.g., when WGS is not available/

the paediatric perspective. An actionable PGx result reported in a

required)—the

concepts

behind

the

development of

a

PGx

4
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“passport”46 with a lifelong PGx record47 have become a reality that
urgently needs further exploration within paediatric healthcare policy

2.2 | The need for separate paediatric PGx
evidence

and practice. With appropriate data retention policies, WGS could
represent the once in a lifetime test after which it would be possible

When reflecting on the need for more paediatric data in order to

to routinely access the PGx data at any point in a child's lifetime

implement evidence-based PGx testing in children, it is important to

when they need a relevant drug prescribing. Such an approach would

consider two fundamental questions: firstly, is separate paediatric

require the development of robust standard operating procedures

PGx evidence always needed? Secondly, if separate paediatric PGx

(SOPs) that incorporate prospectively planned periodic data re-

studies are not always essential, when is it appropriate to extrapolate

analysis to identify PGx variants which have since become clinically

adult pharmacogenomic data to adolescents, children or even infants?

actionable (following new research findings), as this information

In the field of paediatric clinical pharmacology, the traditional mantra

would need to be updated in individuals' PGx records in a timely

had always been that ‘children are not small adults’,55 although it has

fashion.

been increasingly recognised that, in terms of pharmacokinetics, it can

Beyond the adoption of widespread genomic testing into

be argued that “children are small adults, neonates are immature chil-

healthcare services, there are other ways in which PGx testing for

dren”.56 For those drugs where there is an actionable pharmacogene,

children is likely to emerge. Home PGx testing is already available to

this will typically be because of the pharmacogenetic effect on either

(adult) patients themselves via direct-to-consumer (DTC) routes48,49

the PK or PD of the drug in question.

(although not all DTC results are consistent with regulatory guide-

Given that most PGx data have been generated in adult

lines). The utility of these services in children is not clear and it is likely

populations,14,57 it therefore needs to be established, to what extent

that their availability (and related legislation) will vary in different juris-

(if any) adult PGx data can safely be extrapolated to the paediatric

dictions, but it will be important to recognise that parents may seek to

population for each relevant drug/gene pair and the related prescribing

use them for their children.

indication(s). Several factors must be considered to determine the
appropriateness of extrapolation, including the natural history of the
disease progression and response to the proposed therapeutic

2.1
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Assessing PGx evidence

intervention, the likely (or known) exposure–response profile, and the
applicability of adult PD measures to children.58,59 The EMA has

Expert PGx consortia have researched and summarised much of the

acknowledged in its reflection paper on paediatric extrapolation that

considering data from

“gaps in knowledge of intrinsic factors related to organ maturation and

the numerous previous randomised controlled trials (RCTs) in (mainly

ontogeny of enzymatic and transport functions or pharmacogenetics

adult) patients that have demonstrated the clinical utility of PGx

[…], particularly in the youngest age groups of the paediatric population

testing. As implementation initiatives progress, it will be important

are sources of uncertainties and can affect the reliability in the

to synthesise and analyse the cumulative evidence from PGx studies

predictions”.60 It will be essential for researchers to further characterise

involving children, which will require consideration of both the quan-

the role of ontogeny in relation to developmental PGx, particularly with

tity and quality of evidence available. Requiring separate paediatric

respect to the age-related changes in expression of drug-metabolising

(or adult) RCTs to establish the clinical relevance of every single PGx

enzymes (DME) and transporters, exploring how these dynamic

gene/drug pair would prove impractical and unethical, as well as

processes influence the clinical relevance of known pharmacogenes

being unnecessary.52 It also ignores the potential benefits of using

from birth to adulthood.61,62 This research will be especially important

either PGx panel or approaches based on next generation sequenc-

in the youngest age groups (i.e., patients under 2 years of age) where

ing (NGS). It would be logical to approach PGx information (using

pharmacological variability—particularly that derived from DME

50,51

PGx evidence that is available to date,

data from either drug development or post-marketing studies) on

ontogeny—is most pronounced, and also in those settings where the

the basis of sound pharmacological principles, to include appropriate

indication for a particular drug is unique to paediatrics.

prescribing actions according to specified PGx results, in the same

Evidence should also be sought to validate known PGx associa-

way that drug dose recommendations are often adjusted for patients

tions in children57 and, where possible, to demonstrate the conditions

with renal or hepatic dysfunction, where necessary, without separate

determining suitability of extrapolation using different PGx datasets

trials in these special populations.52 Aronson et al. recently

including data from both adults and children. Given the paediatric PGx

highlighted the inadequate appreciation and utilisation of mechanis-

data that exist and the implementation programmes that have already

tic evidence in drug approval processes (where mechanistic evidence

evolved, it would be valuable to reach consensus regarding the

refers to evidence of different types, e.g. in vivo, ex vivo, in vitro,

acceptability of adopting (or adapting) paediatric PGx guidelines from

clinical, observational or simulation studies, that supports the exis-

other countries or institutions, when there are examples already dem-

tence or details of a particular pharmacological mechanism), in asso-

onstrating the effectiveness and utility of PGx testing in children.63

ciation with an overemphatic focus on the results of clinical studies/

Progress will improve when there is consensus regarding the defini-

53

trials ; within a pharmacogenomic context, there is a risk that this

tion of the threshold of PGx evidence needed for implementation.64

same phenomenon

This process would benefit from involvement of international special-

implementation.54

exacerbates

the ongoing delays in PGx

ist paediatric, clinical genetics and pharmacological societies,

5
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developing collaborative guidelines together with associated educa-

viewpoints of different stakeholders, expected benefits, unintended

tional materials and mutual endorsement, in order to help accelerate

consequences and cost. Examples of key issues that need addressing

implementation processes, as has previously been achieved in other

are briefly summarised in Table 2. Rather than describing different

clinical areas.65–69 Ethically, it is important to avoid unnecessary dupli-

implementation strategies and challenges conceptually,73 specific

70

cation of paediatric PGx research whenever possible ; it is therefore

examples are given below based on the paediatric PGx implementa-

essential to synthesise existing evidence from PGx research and

tion experiences and future plans from three countries.

implementation, so that the lessons learned can enable adoption elsewhere to be streamlined and accelerated.

3.1 | Implementation experience to date and
lessons learned

3 | I M P L E M E N T I N G P G X TE S T I N G I N
PAEDIATRICS: STRATEGIES AND
C HA L L E N G E S

The next section summarises relevant examples of PGx implementation from different countries, with reference to the structure of the
healthcare system where relevant, and the key lessons learned.

The translation of scientific knowledge into healthcare policy and
practice is a complex process,71 but strategic change is now supported

3.1.1

|

Canada

by the ever-growing field of implementation science.72 When planning paediatric PGx policy, healthcare leaders, managers and PGx

Direct provision of healthcare in Canada is a provincial responsibility,

experts must consider the issues described above in addition to

with federal oversight of national issues such as drug and device

TABLE 2

Logistics of implementing PGx testing in paediatrics

Issue

Challenge

Potential solution

Indication for PGx testing

Clinicians and pharmacists may feel
uncertain when testing is required

Clear paediatric PGx guidelines with
integration into electronic prescribing
systems and protocols, with PGx
champions in each clinical area

Reporting

Insufficient standardisation of PGx reports
will impede interpretation and use of
results

Standardised PGx report format, with
educational modules to support
prescribers, and local PGx web portal and
helpline for queries

PGx result transfer

Inadequate mechanisms for data transfer/
retention between different healthcare IT
systems

Unified or interoperable EHRs between
primary and secondary care and
pharmacists in which PGx data is stored
life long

Data retention

PGx results may get lost and the
information will not be retained in the
patient's lifelong EHR

Use of PGx cards or PGx QR codes linked
to smartphone app (compatible with
national health systems) and IT to enable
linkage to local/centralised lifelong EHR

Data curation

Research updating PGx knowledge will not
be checked against historical PGx results

PGx data repositories will allow original
data to be revisited and reports updated
periodically

Accountability

Prescribers including physicians,
pharmacists, nurse prescribers, may not
know how to use PGx information and it
will be wasted

Proactive multidisciplinary education with
CDS tools embedded in e-prescribing
software alerting prescribers to
actionable PGx variants

Coding

PGx testing and results are not linked to
appropriate standardised clinical coding
terms

Coding dictionaries need to be updated in
discussion with PGx experts

Cost

It is unclear who should pay for PGx testing

Cost allocations need predefining during
implementation planning

Cascade testing

There are ethical issues surrounding the
implications for family members once
actionable PGx results are known

Guidelines and SOPs should clarify when
testing of a patient's relatives is
recommended and how this will be
communicated to relevant parties

Abbreviations: PGx, pharmacogenomics; EHR, electronic health record; QR, quick response; CDS, clinical decision support; SOP, standard operating
procedure.

6

BARKER ET AL.

approval. Thus, it could be said that Canada has 14 healthcare sys-

centres in seven of the ten provinces in Canada. TPMT variants

tems, and consequently implementation of PGx strategies varies

strongly associated with hearing loss secondary to cisplatin therapy

between provinces, with some provinces being much more active in

(rs1142345, rs1800460, rs1800462, rs56161402, rs6921269)79,80

this space than others, with the partial exception of diseases treated

UGT1A6, SLC28A3 and RARG variants strongly associated with

by national networks, for example children with cancer who are

anthracycline-induced cardiotoxicity (rs17863783, rs7853758 and

treated pursuant to national guidelines. It should be noted that, even

rs2229774)81–83 and TPMT and NUDT15 variants for thiopurine-

with these guidelines in place and despite TPMT genotyping being

induced myelosuppression (rs1142345, rs1800460, rs1800462,

considered a standard of care, availability still varies between prov-

rs56161402,

inces. As in many places, the initial push for pharmacogenetic testing

rs186364861).77,78 Currently, 827 pharmacogenetic tests have been

came from academic researchers, who in the case of Canada have sig-

ordered and results returned in paediatric oncology across Canada.

nificant federal grant support.

rs6921269,

rs116855232,

rs147390019,

CPNDS also established a research programme to understand

Pharmacogenetic testing in broader clinical practice began based

how best to return pharmacogenetic results for robust markers associ-

on discovery, replication and validation work completed by the Cana-

ated with drug outcomes within the three most commonly used clas-

dian Pharmacogenomics Network for Drug Safety (CPNDS) and with

ses of drugs: analgesics, antibiotics and psychotropic drugs.

other research groups. Clinicians wanted to know why specific genes

Robustness was defined as: information on pharmacogenetic variants

were being tested from the range of genetic variants reported in the

included in the drug label by a regulator (e.g., Health Canada, the US

literature. Development of peer-reviewed, multidisciplinary pharma-

Food and Drug Administration, European Medicines Agency); or publi-

cogenetic clinical practice guidelines based on systematic reviews and

shed, peer-reviewed pharmacogenetic clinical practice guidelines from

74

AGREE II

75

76

and

an established expert group (CPIC, DPWG or CPNDS); or variants

published thiopurine guidelines were used.77,78 For the cisplatin and

with drug outcome associations with odds ratio ≥ 3 in at least three

anthracycline guidelines, key questions to be answered were: (1) Who

independent populations (see Table 3). To date, 222 pharmacogenetic

should be tested? (2) Which variants should be tested for? and

tests have been ordered and results returned for these three classes

(3) What therapeutic recommendations should be made if variants are

of drugs in three provinces (British Columbia, Ontario, Quebec). Like

found?

in other countries such as the US, commercial pharmacogenetic panels

were developed for cisplatin

and anthracyclines,

The CPNDS began the implementation of pharmacogenetic test-

are available and accessed throughout Canada by some patients.

ing into clinical practice in 2012, focusing specifically on the imple-

Some private insurers are paying for pharmacogenetic testing in spe-

mentation of tests in paediatric oncology at ten paediatric oncology

cific instances.

TABLE 3

CPNDS PGx testing panel for antibiotics, analgesics and mental health drugs

Drugs

Adverse drug reactions

Genes

Hearing loss, deafness

MT-RNR1

Dapsone/sulfonamides

Haemolytic anaemia

G6PD

Rifampin/isoniazid/pyrazinamide

Serious liver injury

NAT2

CNS depression, therapeutic failure, death

CYP2D6

Rationale

ANTIBIOTICS PGx PANEL
Aminoglycosides

ANALGESICS PGx PANEL
Codeine
Hydrocodone
Oxycodone

CYP2D6
CNS depression, death

Tramadol

CYP2D6
CYP2D6

MENTAL HEALTH PGx PANEL
Mood disorders
Carbamazepine

Severe cutaneous reactions

Phenytoin

HLA-B, HLA-A
HLA-B, CYP2C9

ADHD
Atomoxetine

Therapeutic failure

CYP2D6

Antidepressants
SSRIs (e.g., paroxetine)
SNRIs (e.g., venlafaxine)

Therapeutic failure

CYP2D6, CYP2C19
CYP2D6

Abbreviations: PGx, pharmacogenomics; SNRI, serotonin-norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitors.
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3.1.2

|

The Netherlands

3.1.3

|

United Kingdom

A landmark event in the clinical implementation of pharmacogenetics

Currently paediatric PGx testing in the UK mainly takes place in

in the Netherlands was made in 2005 when the Royal Dutch

specialist contexts or research studies, examples of which are given

Pharmacist Association (KNMP) founded the Dutch Pharmacogenetics

below.

Working Group.32 This multidisciplinary working group consisting of

In paediatric haemato-oncology, TPMT PGx testing is now rou-

physicians and pharmacists writes pharmacogenetic guidelines based

tine for patients due to receive mercaptopurine as part of the che-

on systematic literature reviews of drug/gene pairs. To date, more

motherapy regime for childhood acute lymphoblastic leukaemia

than 100 different drug/gene pairs have been assessed and guidelines

(ALL).38 The implementation of routine testing followed many years

are available for 47 drugs. Recently, the DPWG guidelines were

of research,90 which had investigated TPMT genetic polymorphisms

endorsed by the European Association of Clinical Pharmacology and

in relation to clinically relevant endpoints, including the prevention

Therapeutics84

of potentially fatal myelotoxicity associated with TPMT deficiency,

and

the

European

Association

of

Hospital

Pharmacists.85

optimal dosing of mercaptopurine,91 ALL clinical outcomes92,93 and

Originally DPWG recommendations focused on patients with a

the importance of genotype–phenotype correlation.94 The details of

known genotype. However, DPWG has also started to recommend

TPMT pharmacogenomics are reviewed elsewhere77 and the signifi-

testing, since the creation of the Clinical Implication Score, a system

cance of standardising nomenclature has been emphasised.95,96

that identifies the drugs for which specific PGx testing is needed

Notably, the infrastructure to conduct this TPMT research effi-

prior to prescribing.86 The score is assigned to all actionable drug/

ciently in the UK was in place because of the pre-existing clinical

gene pairs and has three categories for testing: “potentially

trials networks for childhood cancers; paediatric oncology has been

beneficial,” “beneficial,” and “essential”. Currently the score “essen-

recognised internationally as the “subspecialty in which research

tial” is assigned to 14 drug/gene combinations comprising 11 drugs

defines the standard of care”.97 Testing of NUDT15 is not currently

including clopidogrel (CYP2C19), azathioprine/6-MP (TPMT) and

standard of care in the UK, but testing can be accessed if required.

capecitabine/5-FU (DPYD). The utility of DPYD in paediatrics is lim-

A pre-existing paediatric clinical research network which fully inte-

ited as fluoropyrimidines are only used to treat rarer solid tumours in

grates medical research into routine patient care, with ongoing trials

this population (e.g., naso-pharyngeal carcinoma). The clinical recom-

into which PGx studies can be incorporated, is invaluable.98 Similar

mendations of the DPWG are available at point of care through

trials networks and collaborative clinical groups will remain

incorporation in more than 90% of electronic prescribing systems

pivotal in facilitating PGx research and also provide a robust infra-

and pharmacy order entry systems.

structure within which to disseminate and implement new PGx

The most widely adopted PGx test in the Netherlands is test-

recommendations.99–101

ing for variants in DPYD to prevent fluoropyrimidine toxicity. A

Some research studies aim specifically to implement PGx within

recent evaluation reported that over 85% of patients were tested

defined routine care settings, such as the Pharmacogenetics to Avoid

prior to start of treatment.87 Other PGx tests that are generally

Loss Of Hearing (PALOH) study.102,103 PALOH is a clinical implemen-

well accepted include TPMT (mercaptopurine and azathioprine in

tation study aiming to investigate a new point-of-care (POC) PGx test-

paediatrics), CYP2C19 (clopidogrel) and UGT1A1 (irinotecan), but the

ing device to identify neonates at risk of aminoglycoside-induced

level of implementation is highly variable with specialised and aca-

hearing loss (secondary to the genetic variant m.1555A>G).102 This

demic centres having the highest adoption rates. PGx testing is

study is recruiting in Liverpool and Manchester, but the findings will

mostly performed by 10–15 laboratories that are part of clinical

be of relevance to neonatal units across the country, particularly if

chemistry, hospital pharmacy or clinical genetics departments. In

they support the introduction of the new POC PGx test as part of

recent years, the number of tests performed in primary care has

standard neonatal care. PALOH is funded by the NIHR Invention for

expanded and in response the Dutch College of General Practi-

Innovation (i4i) programme, which is focused on early-stage collabora-

tioners has issued a point of view on pharmacogenetics.88 More

tive studies, involving academic, NHS and industry partners, and

recently also the Dutch Society for Psychiatry has released a PGx

deemed to have commercial potential with scope for future imple-

89

mentation within the NHS.104,105 The study is also supported by the

guidance document.

Most PGx testing in the Netherlands is reactive, i.e. in response

NIHR Manchester Biomedical Research Centre (BRC)103,106 in part-

to the prescription of a drug with a potential PGx recommendation.

nership with a charity107 and a local small–medium enterprise (SME).

However, in paediatric clinical genetics WES has become standard

The NIHR BRCs all involve collaborative partnerships between

practice and, as mentioned above, this offers the opportunity to

universities and NHS teaching hospitals, with the aim of translating

repurpose existing diagnostic WES data for pharmacogenomics to

scientific research into patient benefit.108,109 This example again dem-

enable pre-emptive testing. Recently it was shown that meaningful

onstrates the importance of appropriate research networks with an

pharmacogenetic profiles for seven of 11 important pharmacogenes

adequately resourced infrastructure to support delivery of PGx

can be successfully extracted,

43

although there were limitations with

studies.
Historically, PGx testing approaches and availability within the

this technique, with some variations in established pharmacogenes
(e.g., CYP2C19 and CYP2D6) not identified.

UK

were

somewhat

heterogeneous

and

non-standardised.110
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However, there have recently been large changes to the Genomic

utility, and the pharmacoeconomics of proposed paediatric PGx

Medicine infrastructure in the NHS, which will impact upon future

implementation strategies will need detailed evaluation.119,120

PGx testing implementation. NHS England delivered a report in 2015

Prompt information sharing, either through peer-reviewed publica-

describing its focus on “improving outcomes through personalised

tions or paediatric PGx networks, will enable the collaborative PGx

medicine”, which included the aim of delivering whole genome

community to learn together to build adaptable, responsive imple-

sequencing for specific conditions by 2020.111 To support this aim, a

mentation models that can be applied to different healthcare sys-

series of multidisciplinary genomic education initiatives have been

tems.121,122 Implementation initiatives should consider paediatric

implemented, which are discussed further below. A dedicated PGx

drug utilisation patterns in different countries and how these will

working group has been created composed of national experts aiming

impact upon the practical relevance of PGx recommendations. It

to prioritise actionable gene/drug pairs.112 At the time of writing, the

will also be important to continue to share lessons learned about

formal recommendations of this working group are expected to be

implementation across borders so that paediatric PGx benefits can

published in the near future and, while initial phases are understood

become available globally when resources permit, as previously

to have focused on implementation of PGx testing in adults, it is

advocated

anticipated that consideration of paediatrics will follow soon after-

Initiative.123,124

by

the

PharmacoGenetics

for

Every

Nation

wards. The infrastructure provided by the NHS Genomic Medicine

Effective implementation will require early input from key stake-

Service, underpinned by a coordinated national network of Genomic

holders, some of whom will vary depending on local and institutional

Laboratory Hubs and a National Genomic Test Directory, into

contexts. Our recommendations for stakeholders to invite to PGx

which PGx testing can be integrated, has the potential to support

planning teams are summarised in Table 4. The importance of advo-

delivery of an efficient, cost-effective national paediatric PGx testing

cacy for implementation from experts within the relevant specialty

programme.

fields needs to be recognised and incorporated into planned educational strategies, together with identification of PGx champions in
each discipline who can help to support implementation on the front

4 | RECOMMENDATIONS FOR PGX
IMPLEMENTATION APPROACHES IN
PAEDIATRICS

line. Suggested members for the paediatric PGx multidisciplinary team

The adoption of PGx guidelines into normal clinical practice will

4.1

are shown in Figure 1.

|

Embedding education in PGx programmes

require careful orchestration of national, regional and institutional
implementation strategies; these should ideally include CDS tools

A critical aspect of implementing and “mainstreaming” paediatric PGx

fully integrated into the electronic health record (EHR),113 delivered

testing will be ensuring that concise educational material is developed

in parallel with a specialist PGx consulting service. Recommenda-

for all stakeholders in parallel with the implementation plan. Relevant

tions regarding paediatric PGx needs and implementation strategies

stakeholders will include practising paediatricians (including hospital

do not necessarily need to be segregated from the activities of PGx

consultants, registrars/residents and community paediatricians), gen-

consortia dedicated to developing PGx practice guidelines and the

eral practitioners, hospital/community pharmacists, nurses and PGx

approaches used for adult patients; for example, in the United

analytical laboratory scientists. Educational programmes need to pro-

States, three children's hospitals were involved from August 2012 in

vide adequate information about the principles behind the new test-

phase II of the Electronic Medical Records and Genomics (eMERGE)

ing recommendations, indications, cost and, most importantly, the

Network,114,115 which includes extensive PGx implementation

clinical relevance to patients. Inadequate or ill-timed multiprofessional

116

A review of the integration of PGx into the US system

education could jeopardise the success of implementation, for exam-

has also recently been published.117 There are clear advantages of

ple through contributing to inappropriate use of PGx testing, lack of

integrating

nationwide

uptake or misinterpretation of results, and therefore a well-planned

approaches, rather than postponing paediatric initiatives until an

education strategy must be embedded within the implementation

unknown future point, in order to avoid children experiencing

plan. The importance of this extends beyond pharmacogenomics

unnecessary delays in receiving the benefits of pharmacogenomics

alone, and to improve “genomic medicine preparedness” (in its broad-

in practice.

est sense) among healthcare professionals, interprofessional, interdis-

research.

paediatric

PGx

implementation

into

It is recommended that paediatric PGx implementation planning

ciplinary educational programmes should be developed126 and the

in different nations is informed by the available evidence, experi-

material should concomitantly be adapted for undergraduate students

ence and implementation science. Programme delivery should be

in each discipline.

continually monitored for clinically relevant outcomes, evaluating

Inspiration can be taken from various pre-existing educational

predefined metrics of success and cost-effectiveness. As the costs

initiatives, including, for example, the Health Education England

of genomic testing have diminished,118 PGx testing has become

(HEE) Genomics Education Programme, which has developed high-

more affordable and therefore more accessible. This apparent

quality educational modules targeted towards professionals and stu-

affordability does not alone guarantee cost-effectiveness or clinical

dents from different disciplines, and these educational programmes
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TABLE 4

Stakeholders to invite in paediatric PGx implementation planning

Group

Examples of inclusion or recommended representatives

Physicians
Paediatricians

Both subspecialist consultants and general paediatricians should be involved in implementation planning

Clinical geneticists

Geneticists and genetic counsellors with PGx expertise125

Clinical pharmacologists

Physicians and pharmacists with expertise in paediatric clinical pharmacology and/or PGx

GPs and community
doctors

General GPs and those with a special interest in child health

Pharmacists
Hospital

Including representation from specialist hospitals and local hospitals

Community

Representatives from general community pharmacies

Academic and laboratory experts
Scientists

PGx experts from genomic laboratories and clinical academia

Nurses
Nurse prescribers

Advanced nurse practitioners and clinical nurse specialists who prescribe for children in relevant contexts

Other groups
Patients

Lay representation on PGx working groups and committees

Funders

Include management representation and engage early with commissioners

Trial coordinators

Research network leads and trial coordinators can advise on integrating planning PGx studies into existing paediatric
research networks

F I G U R E 1 Healthcare professions and other stakeholders who could contribute to a paediatric pharmacogenomics multidisciplinary team
(MDT) meeting

have been formally recognised as a core component of implementing
Genomic

Medicine

within

the

NHS.127

The

many different settings,129–134 including undergraduate curricula,135

Ubiquitous

and it will be important to tailor pre-existing material specifically

Pharmacogenomic (U-PGx) e-learning platform also provides open

towards paediatrics in order to keep it relevant and to make it suit-

access online learning materials.128 Furthermore, there is a wealth of

able for CPD (continuing professional development) at a postgradu-

educational literature relating to pharmacogenomics programmes in

ate level.
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4.2

|

Integrating research with implementation

pharmacogenomic testing delivered with a cost-effective, evidencebased and sustainable strategy.

In addition to education, PGx research needs to be similarly embedded in any paediatric implementation strategy. The evidence based

AC KNOW LEDG EME NT S

supporting PGx recommendations will constantly grow and protocols

C.I.S.B. and T.H. have been supported by the National Institute for

will, as always, need to be regularly updated. Demands for ever more

Health Research (NIHR) Biomedical Research Centre at King's College

research prior to implementation, in order to increase the quantity of

London (KCL). D.H. has been supported by the NIHR Alder Hey Clini-

evidence available to inform the implementation process, need to be

cal Research Facility (CRF). This is a summary of independent research

weighed against the risks of further delays to implementation and the

carried out at the National Institute for Health Research (NIHR) Alder

right balance must be struck.54 Integrating research into implementa-

Hey Clinical Research Facility. The views expressed are those of the

tion, for example through prospective ethical approvals for gathering

author(s) and not necessarily those of the NHS, the NIHR or the

PGx data into curated repositories, can help to overcome this barrier

Department of Health. C.I.S.B. is funded by the National Institute for

and develop a systematic infrastructure for improving the population

Health Research as an Academic Clinical Fellow. The research con-

PGx evidence base.

ducted by B.C. and G.G. at the Canadian Pharmacogenomics Network
for Drug Safety (CPNDS) at the University of British Columbia is
funded by Genome Canada, Genome BC, the Canadian Institutes of

5

|

THE FUTURE

Health Research, with additional support from British Columbia's Provincial Health Services Authority, BC Children's Hospital Foundation

Continued international collaboration and cooperation will enable the

and Health Canada.

PGx community to realise the potential of precision medicine to contribute meaningfully to optimal pharmacotherapy for children.136 As

COMPETING INTER ESTS

the omics scientific technologies continue to grow, the remit of PGx

G.G. holds a Genomic Applications Partnership Program grant

will expand to incorporate understanding of new domains such as

from

pharmacotranscriptomics and metabolomics.137 Updated, curated

required matching funding from a commercial partner provided by

data-sharing initiatives underpinned by robust information gover-

Dynacare.

Genome

Canada

and

Genome

British

Columbia

with

nance will prove invaluable in advancing paediatric PGx science. Ulti-

A.H.M. has received research grants outside the submitted work

mately, evidence-based PGx in practice will aim to provide clear and

from GSK, Boehringer Íngelheim and Vertex, is the PI of a P4O2

timely PGx results to paediatric prescribers, supported by high quality

(Precision Medicine for more Oxygen) public private partnership spon-

genomic education resources, and continually informed by a cycle of

sored by Health Holland involving many private partners that contrib-

improvement incorporating the latest results of research, audit and

ute in cash and/or in kind (Boehringer Ingelheim, Breathomix, Fluidda,

stakeholder feedback. It will also be important to work towards

Ortec Logiqcare, Philips, Quantib-U, Roche, Smartfish, SODAQ,

harmonisation of paediatric recommendations across the PGx consor-

Thirona, TopMD and Novartis), and she has served on advisory boards

tia and regulatory agencies to help build internationally recognised

for AstraZeneca, GSK and Boehringer Ingelheim with money paid to

PGx standards.34,138

her institution.
M.R. holds the CIHR-GSK Chair in Paediatric Clinical Pharmacology at the University of Western Ontario and is a co-investigator on a

6

|

C O N CL U S I O N S

Genomic Applications Partnership Program grant from Genome
Canada and Genome British Columbia with required matching funding

Children deserve the benefits of genomic medicine including PGx-

from a commercial partner provided by Dynacare. M.R. holds

informed therapies based on strong evidence coupled with affordable

unrelated grants from the National Science and Engineering Council,

implementation. It is inevitable that there are many challenges when

the Canadian Institutes of Health Research and the Academic Medical

introducing new paediatric pharmacogenomic testing strategies into

Association of Southwestern Ontario.

any complex healthcare system. However, with international collabo-

B.C. holds a Genomic Applications Partnership Program grant

ration and evidence curation, to synthesise implementation success

from Genome Canada and Genome British Columbia with required

stories from different countries, we can avoid unnecessary duplication

matching funding from a commercial partner provided by Dynacare.

of research and develop streamlined approaches to pharmacogenomic

B.C. is also an advisor for pharmacogenetic testing at the

implementation strategies. As the genomic medicine revolution is well

UnitedHealth Group.

underway, collaborative efforts of the pharmacogenomic community

All the other authors declare they have no conflicts of interest.

will continue to bring PGx benefits to the bedside, supported by the
infrastructure of well-funded paediatric research networks. It is essen-

CONT RIB UTOR S

tial that a pro-active dialogue with the paediatric workforce continues

This study was conceived by C.I.S.B. All authors contributed to the

to be nurtured, to ensure children benefit from improved access to

writing, editing and overall content of the manuscript.
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